clofazimine has been researched along with Cystic Fibrosis of Pancreas in 6 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this case report the potential drug-drug interaction between cytochrome P450 (CYP) 3A4 substrates tezacaftor-ivacaftor and CYP3A4/5 inhibitor clofazimine is investigated in a patient with cystic fibrosis." | 4.12 | No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report. ( Kemper, EM; Mathôt, RAA; Mouissie, LM; Terheggen-Lagro, SWJ; Vonk, SEM, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cameron, LH | 1 |
| Peloquin, CA | 1 |
| Hiatt, P | 1 |
| Mann, M | 1 |
| Starke, JR | 1 |
| Faircloth, J | 1 |
| McNeil, JC | 1 |
| Patel, A | 1 |
| Ruiz, F | 1 |
| Vonk, SEM | 1 |
| Terheggen-Lagro, SWJ | 1 |
| Mouissie, LM | 1 |
| Mathôt, RAA | 1 |
| Kemper, EM | 1 |
| Hong, E | 1 |
| Almond, LM | 1 |
| Chung, PS | 1 |
| Rao, AP | 1 |
| Beringer, PM | 1 |
| Siegel, SAR | 1 |
| Griffith, DE | 1 |
| Philley, JV | 1 |
| Brown-Elliott, BA | 1 |
| Brunton, AE | 1 |
| Sullivan, PE | 1 |
| Fuss, C | 1 |
| Strnad, L | 1 |
| Wallace, RJ | 1 |
| Winthrop, KL | 1 |
| Thomson, R | 1 |
| Banaschewski, B | 1 |
| Verma, D | 1 |
| Pennings, LJ | 1 |
| Zimmerman, M | 1 |
| Ye, Q | 1 |
| Gadawa, J | 1 |
| Dartois, V | 1 |
| Ordway, D | 1 |
| van Ingen, J | 1 |
| Ufer, S | 1 |
| Stapleton, K | 1 |
| Hofmann, T | 1 |
6 other studies available for clofazimine and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis.
Topics: Child; Clofazimine; Cystic Fibrosis; Humans; Mycobacterium Infections, Nontuberculous; Nontuberculou | 2022 |
No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report.
Topics: Adolescent; Aminophenols; Anti-Inflammatory Agents; Benzodioxoles; Chloride Channel Agonists; Clofaz | 2022 |
Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.
Topics: Anti-Bacterial Agents; Benzodioxoles; Clarithromycin; Clofazimine; Cystic Fibrosis; Cystic Fibrosis | 2022 |
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Clofazimine; Cystic Fibrosis; Drug Resistance, Bacter | 2023 |
Inhaled therapies for NTM disease - The way forward?
Topics: Aerosols; Clofazimine; Cystic Fibrosis; Humans; Mycobacterium Infections, Nontuberculous; Nontubercu | 2019 |
Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Biological Availability; Clofa | 2019 |